Press releases
- IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
- IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
- /C O R R E C T I O N -- IDEAYA Biosciences, Inc./
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
- IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
More ▼
Key statistics
As of last trade IDEAYA Biosciences Inc (30J:BER) traded at 35.20, -21.78% below its 52-week high of 45.00, set on Feb 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.20 |
---|---|
High | 35.20 |
Low | 35.20 |
Bid | 34.60 |
Offer | 35.60 |
Previous close | 35.00 |
Average volume | 16.00 |
---|---|
Shares outstanding | 75.69m |
Free float | 74.84m |
P/E (TTM) | -- |
Market cap | 3.00bn USD |
EPS (TTM) | -2.00 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 13:45 BST.
More ▼